Activities of Quinoxaline, Nitroquinoxaline, and [1,2,4]Triazolo[4,3-a]quinoxaline Analogs of MMV007204 against Schistosoma mansoni-Reference-Cited by-同舟云学术

Activities of Quinoxaline, Nitroquinoxaline, and [1,2,4]Triazolo[4,3-a]quinoxaline Analogs of MMV007204 against Schistosoma mansoni

Published:2021-02-17 Issue:3 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Debbert Stefan L.¹^ORCID,Hintz Mikaela J.¹,Bell Christian J.¹,Earl Kenya R.¹,Forsythe Grant E.¹,Häberli Cécile²³,Keiser Jennifer²³^ORCID

Affiliation:

1. Department of Chemistry, Lawrence University, Appleton, Wisconsin, USA

2. Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland

3. University of Basel, Basel, Switzerland

Abstract

The reliance on one drug, praziquantel, to treat the parasitic disease schistosomiasis in millions of people a year shows the need to further develop a pipeline of new drugs to treat this disease. Recently, an antimalarial quinoxaline derivative (MMV007204) from the Medicines for Malaria Venture (MMV) Malaria Box demonstrated promise against Schistosoma mansoni .

Funder

Swiss National Science Foundation

Lawrence University Excellence in Science Fund

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01370-20

Reference36 articles.

1. Human schistosomiasis

2. Susceptibility or resistance of praziquantel in human schistosomiasis: a review